A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma

Abstract

Similar to previously reported studies, PDAC with a <i>KRAS</i> wild type mutational profile has a better prognosis with a longer OS. This improved prognosis is independent of the protocol utilized in therapy for these patients. Our findings suggest that future clinical trials in pancreatic cancer should take into consideration the presence of <i>KRAS</i> mutations in their pre-planned analysis when assessing the efficacy of a novel therapeutic approach. This may be a crucial factor in trial concepts and outcomes.